Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase

Cancer Gene Therapy

Volumn 10, Issue 1, 2003, Pages 23-29

  Parker, William B ^a   Allan, Paula W ^a   Hassan, Abdalla E A ^a   Secrist III, John A ^a   Sorscher, Eric J ^b   Waud, William R ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

2 fluoro 2 deoxyadenosine; 9 (2 deoxy D ribofuranosyl) 6 methylpurine; 9 D arabinofuranosyl 2 fluoroadenine 5 monophosphate; E. coli purine nucleoside phosphorylase; Gene therapy

Indexed keywords

2' DEOXY 2 FLUOROADENOSINE; 9 (2 DEOXY BETA DEXTRO RIBOFURANOSYL) 6 METHYLPURINE; 9 BETA DEXTRO ARABINOFURANOSYL 2 FLUOROADENINE 5' MONOPHOSPHATE; ADENOSINE DERIVATIVE; FLUDARABINE; PHOSPHATE; PRODRUG; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DNA VECTOR; DRUG ACTIVATION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ESCHERICHIA COLI; GLIOMA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DEOXYADENOSINES; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; GENE THERAPY; GENETIC VECTORS; GLIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; PURINE-NUCLEOSIDE PHOSPHORYLASE; RETROVIRIDAE; TRANSFECTION;

ANIMALIA; ESCHERICHIA COLI;

EID: 0037276433     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700520     Document Type: Article

References (21)

1. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr. Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines. Gene Ther. 1994;1:233-238.
2. Parker WB, King SA, Allan PW, et al. In vivo gene therapy of cancer using E. coli purine nucleoside phosphorylase. Hum Gene Ther. 1997;8:1637-1644.
3. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Ther. 2000;7:1738-1743.
4. Mohr L, Shankara S, Yoon SK, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology. 2000;31:606-614.
5. Park BJ, Brown CK, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999;10:889-898.
6. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther. 1999;10:649-657.
7. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther. 1998;9:16171626.
8. Lockett LJ, Molloy PL, Russell PJ, Both GW. Relative efficiency of tumor cell killing in vitro by two enzymeprodrug systems delivered by identical adenovirus vectors. Clin Cancer Res. 1997;3:2075-2080.
9. Nestler U, Heinkelein M, Lucke M, et al. Foamy virus vectors for suicide gene therapy. Gene Ther. 1997;4:1270-1277.
10. Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. Converting cancer genes into killer genes. Proc Natl Acad Sci USA. 1996;93:4192-4196.
11. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 1995;55:3339-3345.
12. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J Biol Chem. 1998;273:2322-2328.
13. Parker WB, Allan PW, Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol. 1998;55:1673-1681.
14. Noker PE, Duncan GF, El Dareer SM, Hill DL. Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat Rep. 1983;67:445-456.
15. Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 1988;34:485-491.
16. Montgomery JA. Has the well gone dry? Cancer Res. 1982;42:3911-3917.
17. Parker WB, Waud WR, Allan PW, Sorsher EJ, Hassan AE, Secrist JA III. In vivo anti-tumor activity of 2-fluoro-2′-deoxyadenosine (F-dAdo) against human tumors that express the E. coli purine nucleoside phosphorylase gene. Proc Am Assoc Cancer Res. 2001;92 (Abstract 3503).
18. Dykes DJ, Abbott BJ, Mayo JG, et al. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel, Karger. 1992;42:1-22.
19. Montgomery JA, Hewson K. Analogs of 6-methyl-9-β-D-ribofuranosylpurine. J Med Chem. 1968;11:48-52.
20. Hassan AEA, Shortnacy-Fowler AT, Montgomery JA, Secrist JA III. A convenient synthesis of 2′-deoxy-2-fluoroadenosine; a potential prodrug for suicide gene therapy. Nucleosides Nucleotides Nucleic Acids. 2000;19:559-565.
21. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990;17:3-17.